カテゴリ： GlobalData, アメリカ, 企業調査

Strongbridge Biopharma plc (SBBP)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Strongbridge Biopharma plc (SBBP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C7555
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：65
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Strongbridge Biopharma Plc (Strongbridge Biopharma), formerly Cortendo Plc is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases. The company’s marketed product KEVEYIS (dichlorphenamide) is indicated for the treatment of hypokalemic, hyperkalemic, and related variants of primary periodic paralysis, a genetic neuromuscular disorder. Its KEVEYIS holds orphan drug designation in the US. Strongbridge Biopharma’s pipeline products include COR-003 (levoketoconazole) a cortisol synthesis inhibitor for the treatment of endogenous Cushing’s syndrome; and COR-005 a novel somatostatin analog for the treatment of acromegaly with potential use in Cushing’s syndrome and neuroendocrine tumors. The company also provides building franchise around rare endocrine disorders including product candidates for the treatment of endogenous Cushing’s syndrome and acromegaly. Strongbridge Biopharma is headquartered in Trevose, Pennsylvania, the US.

Strongbridge Biopharma plc (SBBP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Strongbridge Biopharma plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Strongbridge Biopharma plc, Medical Devices Deals, 2012 to YTD 2018 10
Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Strongbridge Biopharma Acquires US rights to Keveyis from Taro Pharma 13
Strongbridge Biopharma Acquires Somatoprim from Aspireo Pharma 15
Licensing Agreements 16
Strongbridge Biopharma Enters into Licensing Agreement with Aeterna Zentaris 16
Cortendo Enters into Licensing Agreement with Antisense Therapeutics 17
Equity Offering 19
Strongbridge Biopharma Announces Partial Exercise of Underwriters Option of Public Offering of Shares for USD35.5 Million 19
Strongbridge Biopharma Raises USD25 Million in Public Offering of Shares 21
Strongbridge Biopharma Raises USD3 Million in Private Placement of Shares 23
Strongbridge Biopharma to Raise USD40 Million in Public Offering of Shares 25
Strongbridge Biopharma Plans to Raise Funds through Private Placement of Shares 26
Strongbridge Biopharma Raises USD35 Million in Private Placement of Shares and Warrants 27
Strongbridge Biopharma Raises USD25 Million in IPO 29
Cortendo Raises USD33.2 Million in Private Placement of Shares 31
Cortendo to Raise USD33.2 Million in Private Placement of Shares 32
Strongbridge Biopharma Raises USD26.4 Million in Private Placement of Shares 34
Cortendo Raises USD37.5 Million in Private Placement of Shares 35
Cortendo Raises USD11 Million in Private Placement of Shares 37
Cortendo Raises USD12.6 Million in Private Placement of Shares 38
Cortendo Raises USD2.1 Million in Private Placement of Shares 39
Cortendo Raises USD0.7 Million in Private Placement of Shares 40
Cortendo Raises USD3.1 Million in Private Placement of Shares 41
Strongbridge Biopharma plc – Key Competitors 42
Strongbridge Biopharma plc – Key Employees 43
Strongbridge Biopharma plc – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Recent Developments 45
Financial Announcements 45
Aug 08, 2018: Strongbridge Biopharma reports second quarter 2018 financial results and provides corporate update 45
May 10, 2018: Strongbridge Biopharma Reports First Quarter 2018 Financial Results and Provides Corporate Update 47
Mar 12, 2018: Strongbridge Biopharma Announces Full-Year 2017 Financial Results 49
Nov 14, 2017: Strongbridge Biopharma Provides Corporate Update and Reports Third Quarter 2017 Financial Results 51
Aug 07, 2017: Strongbridge Biopharma Provides Updates on KEVEYIS Launch and Recent Business Highlights, and Reports Second Quarter 2017 Financial Results 54
May 16, 2017: Strongbridge Biopharma Provides Corporate Update and Reports First Quarter 2017 Financial Results 57
Mar 27, 2017: Strongbridge Biopharma Provides Corporate Update and Reports Full-Year 2016 Financial Results 59
Clinical Trials 61
Apr 02, 2018: Strongbridge Biopharma Announces Dosing of First Four Patients in LOGICS, a Second Global Phase 3 Study of RECORLEV (levoketoconazole) in Endogenous Cushing’s Syndrome 61
Mar 18, 2018: Strongbridge Biopharma Announces Presentation of New Data Demonstrating That Levoketoconazole is a Potent Inhibitor of Human Enzymes Controlling Cortisol Synthesis 62
Jun 27, 2017: Strongbridge Biopharma Completes Target Enrollment of 90 Patients in the Phase 3 SONICS Study Evaluating RECORLEV (levoketoconazole) in Endogenous Cushing’s Syndrome 63
Other Significant Developments 64
Sep 25, 2017: Strongbridge Biopharma Launches the Uncovering Periodic Paralysis Genetic Testing Program 64
Appendix 65
Methodology 65
About GlobalData 65
Contact Us 65
Disclaimer 65

List of Tables
Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Strongbridge Biopharma plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Strongbridge Biopharma plc, Deals By Therapy Area, 2012 to YTD 2018 9
Strongbridge Biopharma plc, Medical Devices Deals, 2012 to YTD 2018 10
Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Strongbridge Biopharma Acquires US rights to Keveyis from Taro Pharma 13
Strongbridge Biopharma Acquires Somatoprim from Aspireo Pharma 15
Strongbridge Biopharma Enters into Licensing Agreement with Aeterna Zentaris 16
Cortendo Enters into Licensing Agreement with Antisense Therapeutics 17
Strongbridge Biopharma Announces Partial Exercise of Underwriters Option of Public Offering of Shares for USD35.5 Million 19
Strongbridge Biopharma Raises USD25 Million in Public Offering of Shares 21
Strongbridge Biopharma Raises USD3 Million in Private Placement of Shares 23
Strongbridge Biopharma to Raise USD40 Million in Public Offering of Shares 25
Strongbridge Biopharma Plans to Raise Funds through Private Placement of Shares 26
Strongbridge Biopharma Raises USD35 Million in Private Placement of Shares and Warrants 27
Strongbridge Biopharma Raises USD25 Million in IPO 29
Cortendo Raises USD33.2 Million in Private Placement of Shares 31
Cortendo to Raise USD33.2 Million in Private Placement of Shares 32
Strongbridge Biopharma Raises USD26.4 Million in Private Placement of Shares 34
Cortendo Raises USD37.5 Million in Private Placement of Shares 35
Cortendo Raises USD11 Million in Private Placement of Shares 37
Cortendo Raises USD12.6 Million in Private Placement of Shares 38
Cortendo Raises USD2.1 Million in Private Placement of Shares 39
Cortendo Raises USD0.7 Million in Private Placement of Shares 40
Cortendo Raises USD3.1 Million in Private Placement of Shares 41
Strongbridge Biopharma plc, Key Competitors 42
Strongbridge Biopharma plc, Key Employees 43
Strongbridge Biopharma plc, Subsidiaries 44

List of Figures
Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Strongbridge Biopharma plc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Strongbridge Biopharma plc (SBBP)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Enterprise Therapeutics Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Enterprise Therapeutics Ltd (Enterprise Therapeutics) is a drug discovery company that offers research and development of novel therapies for the treatment of respiratory diseases. The company also identifies novel targets and compounds which reduces the mucus production. It provides therape …
  • Power Engineering Consulting 2 Joint Stock Company (TV2)：企業の財務・戦略的SWOT分析
    Summary Power Engineering Consulting Joint Stock Company 2 (PECC2), a subsidiary of Vietnam Electricity is a power company that designs, investigates, supervises and constructs electric power projects and other industrial and civil utilities. The company provides consultancy services comprise prepar …
  • Allegheny Technologies Incorporated：企業の戦略・SWOT・財務情報
    Allegheny Technologies Incorporated - Strategy, SWOT and Corporate Finance Report Summary Allegheny Technologies Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Saudi Industrial Export Company (4140)：企業の財務・戦略的SWOT分析
    Summary Saudi Industrial Export Company (SIEC) is a chemical providing company that imports, exports and selss specialty chemicals, fertilizers, industrial materials and commodities. The company's fertilizers include diammonium phosphate, sulphur, urea, triple super phosphate, granular triple super …
  • Borealis AG：企業の戦略的SWOT分析
    Borealis AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Hoya Corp (7741)：医療機器：M&Aディール及び事業提携情報
    Summary Hoya Corp (Hoya) is a global med-tech company that manufactures and sells precision devices and instruments built on its advanced optics technologies. Principal products include eyeglass and contact lenses, medical endoscopes, laparoscopic surgical instruments, intraocular lenses, orthopedic …
  • Mosenergo (MSNG)：電力：M&Aディール及び事業提携情報
    Summary Mosenergo, a subsidiary of Gazprom Energoholding LLC, is a power utility. It generates electricity and thermal energy using natural gas, coal, fuel oil, and diesel sources. The company owns and operates power plants: TPP-20, SDPP-3, TPP-9, SPP-1, TPP-21, TPP-8, TPP-11, TPP-16, TPP-12, TPP-17 …
  • Lucasfilm Ltd：企業の戦略的SWOT分析
    Lucasfilm Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • KINeSYS Inc.：企業の戦略・SWOT・財務情報
    KINeSYS Inc. - Strategy, SWOT and Corporate Finance Report Summary KINeSYS Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Bionik Laboratories Corp (BNKL)：企業の製品パイプライン分析2018
    Summary Bionik Laboratories Corp (Bionik) is a medical device company that designs and develops transformational technologies, prosthetics and assisted robotic products and solutions. The company provides rehabilitation technology that senses patient movements and limitations. It provides lower body …
  • Pon Holdings B.V.：企業のM&A・事業提携・投資動向
    Pon Holdings B.V. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Pon Holdings B.V. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Insulet Corp (PODD)-医療機器分野：企業M&A・提携分析
    Summary Insulet Corp (Insulet) is a medical device company that develops, manufactures and distributes OmniPod insulin management system, an insulin infusion system for diabetic patients. OmniPod insulin management system consists of OmniPod, a disposable insulin infusion device and the Personal Dia …
  • PolyNovo Ltd (PNV)：企業の財務・戦略的SWOT分析
    Summary PolyNovo Ltd (PolyNovo), formerly Calzada Ltd, is a medical device company that develops, manufactures and commercializes biodegradable polymers for use in medical devices. The company provides products such as biodegradable temporizing matrix and negative pressure wound therapy dressing sys …
  • PGS ASA (PGS)：企業の財務・戦略的SWOT分析
    PGS ASA (PGS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Chugach Electric Association, Inc.：企業の発電所・SWOT分析2018
    Chugach Electric Association, Inc. - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information o …
  • Medivir AB (MVIR B)：企業の財務・戦略的SWOT分析
    Summary Medivir AB (Medivir) is a pharmaceutical company. It is engaged in drug discovery and development of treatments for cancer.The company offers products under development for the treatment of cutaneous T-cell lymphoma, osteoarthritis, solid tumors, hepatocellular carcinoma and acute myeloid le …
  • Syngen Biotech Co Ltd (8279)-製薬・医療分野：企業M&A・提携分析
    Summary Syngen Biotech Co Ltd (Syngen), a part of Standard Chem& Pharm Co Ltd, is a biotechnology company that specializes in strain identification, micro-organism fermentation, recovery, and purification. The company research, develops, manufactures and distributes active pharmaceutical ingredients …
  • Huhtamaki Oyj：企業のM&A・事業提携・投資動向
    Huhtamaki Oyj - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Huhtamaki Oyj Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Cisco Systems, Inc.：企業の戦略・SWOT・財務情報
    Cisco Systems, Inc. - Strategy, SWOT and Corporate Finance Report Summary Cisco Systems, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • KPMG International Coop：企業の戦略的SWOT分析
    KPMG International Coop - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆